What is Aronora?
Aronora, Inc. is dedicated to pioneering innovative biologic drugs, such as AB002 and AB023, aimed at treating serious hematologic diseases with substantial unmet medical needs. The company's therapeutic focus includes addressing life-threatening blood conditions, particularly for patients requiring anticoagulation during hemodialysis due to end-stage renal disease, and those susceptible to thrombotic complications. Aronora's mission centers on enhancing patient outcomes through the creation of safe and effective hematology treatments.
How much funding has Aronora raised?
Aronora has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2021): $150K with participation from PPP
What's next for Aronora?
With its substantial late-stage funding, Aronora is strategically positioned to accelerate the commercialization of its first-in-class biologic drugs. The capital infusion is expected to fuel further clinical development, regulatory submissions, and market preparation for its lead candidates, AB002 and AB023. This financial backing signals strong investor confidence in Aronora's approach to tackling critical hematologic diseases and its potential to capture significant market share in the specialized biopharmaceutical sector.
See full Aronora company page
